Achaogen Inc (NASDAQ:AKAO) – Leerink Swann lowered their Q3 2018 EPS estimates for Achaogen in a report issued on Monday, October 15th, Zacks Investment Research reports. Leerink Swann analyst A. Fadia now expects that the biopharmaceutical company will post earnings per share of ($1.02) for the quarter, down from their prior estimate of ($0.99). Leerink Swann also issued estimates for Achaogen’s Q4 2018 earnings at ($0.72) EPS.
AKAO has been the subject of several other research reports. Cowen reaffirmed a “buy” rating on shares of Achaogen in a research note on Friday, July 27th. Stifel Nicolaus increased their price objective on shares of Achaogen from $14.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, August 7th. Zacks Investment Research raised shares of Achaogen from a “sell” rating to a “hold” rating in a research report on Friday, August 3rd. BidaskClub downgraded shares of Achaogen from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 18th. Finally, Needham & Company LLC downgraded shares of Achaogen from a “buy” rating to a “hold” rating in a research report on Tuesday, August 7th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $17.03.
Achaogen (NASDAQ:AKAO) last issued its earnings results on Monday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.92) by ($0.19). Achaogen had a negative net margin of 2,286.21% and a negative return on equity of 146.50%. The firm had revenue of $2.56 million during the quarter, compared to the consensus estimate of $1.49 million.
Several hedge funds have recently modified their holdings of AKAO. Stifel Financial Corp bought a new position in Achaogen in the first quarter valued at $134,000. Jane Street Group LLC bought a new position in Achaogen in the first quarter valued at $415,000. Blair William & Co. IL bought a new position in Achaogen in the first quarter valued at $559,000. Sei Investments Co. bought a new position in Achaogen in the second quarter valued at $423,000. Finally, Swiss National Bank grew its position in Achaogen by 12.9% in the first quarter. Swiss National Bank now owns 50,000 shares of the biopharmaceutical company’s stock valued at $648,000 after purchasing an additional 5,700 shares in the last quarter. 60.27% of the stock is owned by institutional investors.
Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Recommended Story: What impact do institutional investors have on markets?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.